Topological polar surface area: A useful descriptor in 2D-QSAR

Current Medicinal Chemistry

Volumn 16, Issue 1, 2009, Pages 21-41

  Prasanna, S ^a   Doerksen, R J ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

2D QSAR; Anti malarial agents; Antitumor agents; ClogP; CMR; GSK 3; Structure activity relationship; Topological polar surface area (TPSA)

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2,4,6 PYRIMIDINE DERIVATIVE; 4 MALEIMIDE DERIVATIVE; 6 ARYL 2 MORPHOLIN 4 YL 4H PYRAN 4 ONE DERIVATIVE; 6 ARYL 2 MORPHOLIN 4 YL 4H THIOPYRAN 4 ONE DERIVATIVE; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTITRYPANOSOMAL AGENT; AROMATASE INHIBITOR; CHOLINESTERASE INHIBITOR; CHROMONE DERIVATIVE; COUMARIN DERIVATIVE; FLAVONOID; FLUOREN 9 YLETHYL AMIDE DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; ISOFLAVONE DERIVATIVE; MALEIMIDE DERIVATIVE; MELAMINE DERIVATIVE; MONOAMINE OXIDASE B INHIBITOR; NAPHTHOCARBAZOLE DERIVATIVE; NU 7441; PHOSPHODIESTERASE V INHIBITOR; PYRAZOLOPYRIDINE DERIVATIVE; PYRIDOACRIDINE ALKALOID DERIVATIVE; PYRIMETHAMINE; TACRINE; TRIARYL 2 SULFONE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE; DRUG; ENZYME INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANTIBACTERIAL ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BIOLOGICAL ACTIVITY; BREAST CANCER; CHEMICAL PROCEDURES; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; HUMAN; PROSTATE CANCER; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SLEEP DISORDER; TOPOLOGICAL POLAR SURFACE AREA; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG ANTAGONISM; SOLUBILITY; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CHOLINESTERASE INHIBITORS; COMPUTER SIMULATION; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOLUBILITY; TRYPANOCIDAL AGENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61949444938     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787002817     Document Type: Review

References (62)

1. Li, S.F.; He, H.D.; Parthiban, L.J.; Yin, H.Q.; Serajuddin, A.T.M. IV-IVC considerations in the development of immediate-release oral dosage form. J. Pharm. Sci., 2005, 94, 1396-417
2. Strazielle, N.; Ghersi-Egea, J.F. Factors affecting delivery of antiviral drugs to the brain. Rev. Med. Virol., 2005, 15, 105-33.
3. Clark, D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci., 1999, 88, 807-14.
4. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem., 2000, 43, 3714-17.
5. Clark, D.E.; Higgs, C.; Wren, S.P.; Dyke, H.J.; Wong, M.; Norman, D.; Lockey, P.M.; Roach, A.G. A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor. J. Med. Chem., 2004, 47, 3962-71.
6. Fink, T.; Bruggesser, H.; Reymond, J.L. Virtual exploration of the small-molecule chemical universe below 160 daltons. Angewandte Chem.-Int. Ed., 2005, 44, 1504-08.
7. Monge, A.; Arrault, A.; Marot, C.; Morin-Allory, L. Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers. Mol. Divers., 2006, 10, 389-403.
8. Russell, M.G.N.; Carling, R.W.; Atack, J.R.; Bromidge, F.A.; Cook, S.M.; Hunt, P.; Isted, C.; Lucas, M.; McKernan, R.M.; Mitchinson, A.; Moore, K.W.; Narquizian, R.; Macaulay, A.J.; Thomas, D.; Thompson, S.A.; Wafford, K.A.; Castro, J.L. Discovery of functionally selective 7,8,9,10-tetrahydro-7,10-ethano-1,2,4-triazolo[3,4]-aphthalazines as GABA(A) receptor agonists at the alpha(3) subunit. J. Med. Chem., 2005, 48, 1367-83.
9. Bartzatt, R.L. Evaluation of pyridine-3-carboxylic acid as a drug carrier by utilizing multivariate methods, structure property correlations, and pattern recognition techniques. Recept. Channels, 2004, 10, 61-71.
10. Clark, D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci., 1999, 88, 815-21.
11. Freitas, M.P. MIA-QSAR modelling of anti-HIV-1 activities of some 2-amino-6-arylsulfonylbenzonitriles and their thio and sulfinyl congeners. Org. Biomol. Chem., 2006, 4, 1154-59
12. Geneste, H.; Amberg, W.; Backfisch, G.; Beyerbach, A.; Braje, W.M.; Delzer, E.; Haupt, A.; Hutchins, C.W.; King, L.L.; Sauer, D.R.; Unger, L.; Wernet, W. Synthesis and SAR of highly potent and selective dopamine D-3-receptor antagonists: Variations on the 1H-pyrimidin-2-one theme. Bioorg. Med. Chem. Lett., 2006, 16, 1934-37.
13. Gerebtzoff, G.; Seelig, A. In silico prediction of blood - Brain barrier permeation using the calculated molecular cross-sectional area as main parameter. J. Chem. Inf. Model., 2006, 46, 2638-50.
14. Katritzky, A.R.; Kuanar, M.; Slavov, S.; Dobchev, D.A.; Fara, D.C.; Karelson, M.; Acree, W.E.; Solov'ev, V.P.; Varnek, A. Correlation of blood-brain penetration using structural descriptors. Bioorg. Med. Chem., 2006, 14, 4888-917.
15. Manley, P.W.; Furet, P.; Bold, G.; Bruggen, J.; Mestan, J.; Meyer, T.; Schnell, C.R.; Wood, J. Anthranilic acid amides: A novel class of antiangiogenic VEGF receptor kinase inhibitors. J. Med. Chem., 2002, 45, 5687-93.
16. Mehrotra, M.M.; Heath, J.A.; Smyth, M.S.; Pandey, A.; Rose, J.W.; Seroogy, J.M.; Volkots, D.L.; Nannizzi-Alaimo, L.; Park, G.L.; Lambing, J.L.; Hollenbach, S.J.; Scarborough, R.M. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists. J. Med. Chem., 2004, 47, 2037-61.
17. Remko, M.; Swart, M.; Bickelhaupt, F.M. Theoretical study of structure, pK(a), lipophilicity, solubility, absorption, and polar surface area of some centrally acting antihypertensives. Bioorg. Med. Chem., 2006, 14, 1715-28.
18. Tan, D.S. Diversity-oriented synthesis: Exploring the intersections between chemistry and biology. Nat. Chem. Biol., 2005, 1, 74-84.
19. Ertl, P. Polar Surface Area. In Molecular Drug Properties: Measurement and Prediction. Mannhold, R.; Kubinyi, H.; Folkers, G., Eds. Wiley-VCH: Weinheim, 2007, 111-126.
20. Garg, R.; Kurup, A.; Mekapati, S.B.; Hansch, C. Cyclooxygenase COX) inhibitors: A comparative QSAR study. Chem. Rev., 2003, 103, 703-31.
21. Hansch, C.; Leo, A. Substituent Constants for Correlation Analysis n Chemistry and Biology. John Wiley and Sons, 1979.
22. Yoshida, K.; Niwa, T. Quantitative structure-activity relationship studies on inhibition of HERG potassium channels. J. Chem. Inf. Model., 2006, 46, 1371-78.
23. Murias, M.; Handler, N.; Erker, T.; Pleban, K.; Ecker, G.; Saiko, P.; Szekeres, T.; Jager, W. Resveratrol analogues as selective clooxygenase-2 inhibitors: Synthesis and structure-activity relationship. Bioorg. Med. Chem., 2004, 12, 5571-78.
24. Shahapurkar, S.; Kawathekar, N.; Chaturvedi, S.C. Quantitative structure activity relationship studies of diaryl thiophen derivatives as selective COX-2 inhibitors. Pharmazie, 2005, 60, 254-58.
25. Liu, R.F.; Sun, H.M.; So, S.S. Development of quantitative strucure-property relationship models for early ADME evaluation in drug discovery. 2. Blood-brain barrier penetration. J. Chem. Inf. Comp. Sci., 2001, 41, 1623-32.
26. Pan, D.H.; Iyer, M.; Liu, J.Z.; Li, Y.; Hopfinger, A.J. Constructing optimum blood brain barrier QSAR models using a combination of 4D-molecular similarity measures and cluster analysis. J. Chem. Inf. Comp. Sci., 2004, 44, 2083-98.
27. Liu, R.F.; So, S.S. Development of quantitative structure-property elationship models for early ADME evaluation in drug discovery. 1. Aqueous solubility. J. Chem. Inf. Comp. Sci., 2001, 41, 1633-39.
28. Turabekova, M.A.; Rasulev, B.F. A QSAR toxicity study of a series of alkaloids with the lycoctonine skeleton. Molecules, 2004, 9, 1194-207.
29. Turabekova, M.A.; Rasulev, B.F. QSAR analysis of the structure-oxicity relationship of aconitum and delphinium diterpene alkaoids. Chem. Nat. Comp., 2005, 41, 213-19.
30. Estrada, E.; Quincoces, J.A.; Patlewicz, G. Creating molecular diversity from antioxidants in Brazilian propolis. Combination of TOPS-MODE QSAR and virtual structure generation. Mol. Divers., 2004, 8, 21-33.
31. Sprous, D.G.; Zhang, J.; Zhang, L.; Wang, Z.L.; Tepper, M.A. Kinase inhibitor recognition by use of a multivariable QSAR model. J. Mol. Graph Model., 2006, 24, 278-95.
32. Li, H.; Yap, C.W.; Ung, C.Y.; Xue, Y.; Li, Z.R.; Han, L.Y.; Lin, H.H.; Chen, Y.Z. Machine learning approaches for predicting compounds that interact with therapeutic and ADMET mated proteins. J. Pharm. Sci., 2007, 96, 2838-60.
33. Hadjipavlou-Litina, D.; Garg, R.; Hansch, C. Comparative quantiative structure-activity relationship studies (QSAR) on nonbenzodiazepine compounds binding to benzodiazepine receptor BzR). Chem. Rev., 2004, 104, 3751-93.
34. Verloop, A.; Hoogenstraaten, W.; Tipker, J. In Drug Design. New York, Academic Press, 1976.
35. Durbin, J.; Watson, G.S. Testing for serial correlation in least squares regression. Biometrika, 1950, 37, 409-28.
36. Doweyko, A.M. 3D-QSAR illusions. J. Comp.-Aided Mol. Des., 2004, 18, 587-96.
37. Ponce, Y.M.; Garit, J.A.C.; Torrens, F.; Zaldivar, V.R.; Castro, E.A. Atom, atom-type, and total linear indices of the "molecular pseudograph's atom adjacency matrix": Application to QSPR/QSAR studies of organic compounds. Molecules, 2004, 9, 1100-23.
38. Anderssen, E.; Dyrstad, K.; Westad, F.; Martens, H. Reducing over-optimism in variable selection by cross-model validation. Chemometrics and Intelligent Laboratory Systems 2006, 84, 69-74.
39. Menichincheri, M.; Ballinari, D.; Bargiotti, A.; Bonomini, L.; Ceccarelli, W.; D'Alessio, R.; Fretta, A.; Moll, J.; Polucci, P.; Soncini, C.; Tibolla, M.; Trosset, J.Y.; Vanotti, E. Catecholic flavonoids acting as telomerase inhibitors. J. Med. Chem., 2004, 47, 6466-75.
40. Calcagnile, O.; Gisselsson, D. Telomere dysfunction and telomerase activation in cancer - a pathological paradox? Cytogenet. Genome Res., 2007, 118, 270-76.
41. Su, B.; Hackett, J.C.; Diaz-Cruz, E.S.; Kim, Y.W.; Brueggemeier, R.W. Lead optimization of 7-benzyloxy 2-(4′-pyridylmethyl)thio soflavone aromatase inhibitors. Bioorg. Med. Chem., 2005, 13, 6571-77.
42. Delfourne, E.; Kiss, R.; Le Corre, L.; Dujols, F.; Bastide, J.; Colignon, F.; Lesur, B.; Frydman, A.; Darro, F. Synthesis and in vitro antitumor activity of phenanthrolin-7-one derivatives, analogues of he marine pyridoacridine alkaloids ascididemin and meridine: Structure-activity relationship. J. Med. Chem., 2003, 46, 3536-45.
43. Routier, S.; Peixoto, P.; Merour, J.Y.; Coudert, G.; Dias, N.; Bailly, C.; Pierre, A.; Leonce, S.; Caignard, D.H. Synthesis and biological evaluation of novel naphthocarbazoles as potential anticancer agents. J. Med. Chem., 2005, 48, 1401-13.
44. Hollick, J.J.; Golding, B.T.; Hardcastle, I.R.; Martin, N.; Richardson, C.; Rigoreau, L.J.M.; Smith, G.C.M.; Griffin, R.J. 2,6- disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase (DNA-PK). Bioorg. Med. Chem. Lett., 2003, 13, 3083-86.
45. Izzard, R.A.; Jackson, S.P.; Smith, G.C.M. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res., 1999, 59, 2581-86.
46. Leahy, J.J.J.; Golding, B.T.; Griffin, R.J.; Hardcastle, I.R.; Richardson, C.; Rigoreau, L.; Smith, G.C.M. Identification of a highly potent and selective DNA-dependent protein kinase (DNAPK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg. Med. Chem. Lett., 2004, 14, 6083-87.
47. Hollick, J.J.; Rigoreau, L.J.M.; Cano-Soumillac, C.; Cockcroft, X.; Curtin, N.J.; Frigerio, M.; Golding, B.T.; Guiard, S.; Hardcastle, I.R.; Hickson, I.; Hummersone, M.G.; Menear, K.A.; Martin, N.M.B.; Matthews, I.; Newell, D.R.; Ord, R.; Richardson, C.J.; Smith, G.C.M.; Griffin, R.J. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure- activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase. J. Med. Chem., 2007, 50, 1958-72.
48. Phiel, C.J.; Wilson, C.A.; Lee, V.M.Y.; Klein, P.S. GSK-3 alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature, 2003, 423, 435-39.
49. Smith, D.G.; Buffet, M.; Fenwick, A.E.; Haigh, D.; Ife, R.J.; Saunders, M.; Slingsby, B.P.; Stacey, R.; Ward, R.W. 3-anilino-4- arylmaleimides: Potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett., 2001, 11, 635-39.
50. Sivaprakasam, P.; Xie, A.H.; Doerksen, R.J. Probing the physicochemical and structural requirements for glycogen synthase kinase- 3 alpha inhibition: 2D-QSAR for 3-anilino-4-phenylmaleimides. Bioorg. Med. Chem., 2006, 14, 8210-18.
51. Witherington, J.; Bordas, V.; Gaiba, A.; Garton, N.S.; Naylor, A.; Rawlings, A.D.; Slingsby, B.P.; Smith, D.G.; Takle, A.K.; Ward, R.W. 6-aryl-pyrazolo[3,4]-bpyridines: Potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett., 2003, 13, 3055-57.
52. Agarwal, A.; Srivastava, K.; Puri, S.K.; Chauhan, P.M.S. Synthesis of 2,4,6-trisubstituted pyrimidines as antimalarial agents. Bioorg. Med. Chem., 2005, 13, 4645-50.
53. Baliani, A.; Bueno, G.J.; Stewart, M.L.; Yardley, V.; Brun, R.; Barrett, M.P.; Gilbert, I.H. Design and synthesis of a series of melamine-based nitroheterocycles with activity against trypanosomatid parasites. J. Med. Chem., 2005, 48, 5570-79.
54. Maser, P.; Luscher, A.; Kaminsky, R. Drug transport and drug resistance in African trypanosomes. Drug Resist. Updates, 2003, 6, 281-90.
55. Cheng, J.F.; Chen, M.; Wallace, D.; Tith, S.; Arrhenius, T.; Kashiwagi, H.; Ono, Y.; Ishikawa, A.; Sato, H.; Kozono, T.; Sato, H.; Nadzan, A.M. Discovery and structure-activity relationship of coumarin derivatives as TNF-alpha inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 2411-15.
56. Bruhlmann, C.; Ooms, F.; Carrupt, P.A.; Testa, B.; Catto, M.; Leonetti, F.; Altomare, C.; Carotti, A. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J. Med. Chem., 2001, 44, 3195-98.
57. Boyd, B. Ongoing progress in the Alzheimer's disease arena. Drug News Perspect., 2000, 13, 425-38.
58. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of monoamine oxidases by functionalized coumarin derivatives: Biological activities, QSARs, and 3D-QSARs. J. Med. Chem., 2000, 43, 4747-58.
59. Epperson, J.R.; Bruce, M.A.; Catt, J.D.; Deskus, J.A.; Hodges, D.B.; Karageorge, G.N.; Keavy, D.J.; Mahle, C.D.; Mattson, R.J.; Ortiz, A.A.; Parker, M.F.; Takaki, K.S.; Watson, B.T.; Yevich, J.P. Chronobiotic activity of N-[2-(2,7-dimethoxyfluoren-9-yl)ethyll-propanamide. Synthesis and melatonergic pharmacology of fluoren- 9-ylethyl amides. Bioorg. Med. Chem., 2004, 12, 4601-11.
60. Lavey, B.J.; Kozlowski, J.A.; Hipkin, R.W.; Gonsiorek, W.; Lundell, D.J.; Piwinski, J.J.; Narula, S.; Lunn, C.A. Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: Identification of a lead and initial SAR studies. Bioorg. Med. Chem. Lett., 2005, 15, 783-86.
61. Shankar, B.B.; Lavey, B.J.; Zhou, G.W.; Spitler, J.A.; Tong, L.; Rizvi, R.; Yang, D.Y.; Wolin, R.; Kozlowski, J.A.; Shih, N.Y.; Wu, J.; Hipkin, R.W.; Gonsiorek, W.; Lunn, C.A. Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies. Bioorg. Med. Chem. Lett., 2005, 15, 4417-20.
62. Wang, Y.G.; Chackalamannil, S.; Hu, Z.Y.; Boyle, C.D.; Lankin, C.M.; Xia, Y.; Xu, R.; Asberom, T.; Pissarnitski, D.; Stamford, A.W.; Greenlee, W.J.; Skell, J.; Kurowski, S.; Vemulapalli, S.; Palamanda, J.; Chintala, M.; Wu, P.; Myers, J.; Wang, P. Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors. Bioorg. Med. Chem. Lett., 2002, 12, 3149-52.